Arcturus Therapeutics (NASDAQ:ARCT) Given “Buy” Rating at HC Wainwright

HC Wainwright reissued their buy rating on shares of Arcturus Therapeutics (NASDAQ:ARCT) in a research note issued to investors on Friday morning,Benzinga reports. HC Wainwright currently has a $63.00 price target on the biotechnology company’s stock.

ARCT has been the topic of a number of other reports. BTIG Research started coverage on Arcturus Therapeutics in a report on Tuesday, January 28th. They set a “buy” rating and a $41.00 price target on the stock. Cantor Fitzgerald reiterated an “overweight” rating on shares of Arcturus Therapeutics in a report on Monday, December 16th. Six investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Arcturus Therapeutics has an average rating of “Buy” and an average target price of $65.00.

Arcturus Therapeutics Stock Up 10.0 %

ARCT stock opened at $18.05 on Friday. Arcturus Therapeutics has a twelve month low of $14.30 and a twelve month high of $45.00. The stock’s 50 day moving average is $17.03 and its 200-day moving average is $19.02. The firm has a market capitalization of $488.97 million, a PE ratio of -8.13 and a beta of 2.62.

Institutional Trading of Arcturus Therapeutics

Several hedge funds have recently made changes to their positions in the company. PDT Partners LLC raised its stake in shares of Arcturus Therapeutics by 20.2% in the fourth quarter. PDT Partners LLC now owns 90,298 shares of the biotechnology company’s stock valued at $1,532,000 after buying an additional 15,154 shares during the period. Schonfeld Strategic Advisors LLC raised its stake in shares of Arcturus Therapeutics by 129.7% in the fourth quarter. Schonfeld Strategic Advisors LLC now owns 849,081 shares of the biotechnology company’s stock valued at $14,409,000 after buying an additional 479,482 shares during the period. Northern Trust Corp raised its stake in shares of Arcturus Therapeutics by 5.6% in the fourth quarter. Northern Trust Corp now owns 256,332 shares of the biotechnology company’s stock valued at $4,350,000 after buying an additional 13,582 shares during the period. Boothbay Fund Management LLC bought a new stake in shares of Arcturus Therapeutics in the fourth quarter valued at $1,000,000. Finally, Virtus ETF Advisers LLC raised its stake in shares of Arcturus Therapeutics by 38.8% in the fourth quarter. Virtus ETF Advisers LLC now owns 4,051 shares of the biotechnology company’s stock valued at $69,000 after buying an additional 1,132 shares during the period. 94.54% of the stock is currently owned by institutional investors.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.